Insider Transactions in Q1 2021 at Bluebird Bio, Inc. (BLUE)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2021
|
Nick Leschly |
BUY
Exercise of conversion of derivative security
|
Direct |
203,355
+39.8%
|
$1,016,775
$5.5 P/Share
|
|
Mar 02
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
39
-0.08%
|
$1,131
$29.58 P/Share
|
|
Mar 02
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
38
-0.08%
|
$1,102
$29.58 P/Share
|
|
Mar 02
2021
|
David Davidson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
42
-0.09%
|
$1,218
$29.58 P/Share
|
|
Mar 02
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
34
-0.08%
|
$986
$29.58 P/Share
|
|
Mar 02
2021
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
444
-0.42%
|
$12,876
$29.58 P/Share
|
|
Feb 17
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
665
-1.37%
|
$18,620
$28.16 P/Share
|
|
Feb 17
2021
|
David Davidson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
698
-1.44%
|
$19,544
$28.16 P/Share
|
|
Feb 17
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
749
-1.83%
|
$20,972
$28.16 P/Share
|
|
Feb 17
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
664
-1.39%
|
$18,592
$28.16 P/Share
|
|
Feb 17
2021
|
Katy Burnett Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
518
-11.22%
|
$14,504
$28.16 P/Share
|
|
Feb 17
2021
|
William D Baird Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
693
-1.91%
|
$19,404
$28.16 P/Share
|
|
Feb 16
2021
|
Nick Leschly |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+14.67%
|
-
|
|
Feb 16
2021
|
Jason Cole Chief Strategy & Financial Off |
BUY
Grant, award, or other acquisition
|
Direct |
15,915
+13.53%
|
-
|
|
Feb 16
2021
|
David Davidson Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,271
+11.11%
|
-
|
|
Feb 16
2021
|
Andrew Obenshain President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
17,065
+16.32%
|
-
|
|
Feb 16
2021
|
Philip D Gregory Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,662
+12.96%
|
-
|
|
Feb 16
2021
|
Katy Burnett Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,427
+31.08%
|
-
|
|
Feb 16
2021
|
William D Baird Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,641
+16.21%
|
-
|
|
Feb 12
2021
|
William D Baird Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,216
-5.33%
|
$54,720
$45.52 P/Share
|
|
Feb 02
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
59
-0.18%
|
$2,655
$45.93 P/Share
|
|
Feb 02
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
38
-0.12%
|
$1,710
$45.93 P/Share
|
|
Feb 02
2021
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
594
-0.68%
|
$26,730
$45.93 P/Share
|
|
Feb 02
2021
|
David Davidson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
63
-0.17%
|
$2,835
$45.93 P/Share
|
|
Feb 02
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
34
-0.14%
|
$1,530
$45.93 P/Share
|
|
Jan 07
2021
|
Ramy Ibrahim Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+50.0%
|
-
|
|
Jan 06
2021
|
William D Baird Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
949
-2.02%
|
$42,705
$45.11 P/Share
|
|
Jan 06
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,754
-3.93%
|
$123,930
$45.11 P/Share
|
|
Jan 06
2021
|
Joanne Smith Farrell COO, Oncology |
SELL
Open market or private sale
|
Direct |
1,287
-2.98%
|
$57,915
$45.11 P/Share
|
|
Jan 06
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
2,358
-3.41%
|
$106,110
$45.11 P/Share
|
|
Jan 06
2021
|
David Davidson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,167
-4.09%
|
$142,515
$45.11 P/Share
|
|
Jan 06
2021
|
Alison Cecily Finger Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,814
-3.43%
|
$81,630
$45.11 P/Share
|
|
Jan 06
2021
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
10,095
-5.32%
|
$454,275
$45.11 P/Share
|
|
Jan 05
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
45
-0.13%
|
$1,980
$44.95 P/Share
|
|
Jan 05
2021
|
Joanne Smith Farrell COO, Oncology |
SELL
Open market or private sale
|
Direct |
42
-0.19%
|
$1,848
$44.95 P/Share
|
|
Jan 05
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
43
-0.12%
|
$1,892
$44.95 P/Share
|
|
Jan 05
2021
|
David Davidson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
48
-0.12%
|
$2,112
$44.95 P/Share
|
|
Jan 05
2021
|
Alison Cecily Finger Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
40
-0.15%
|
$1,760
$44.95 P/Share
|
|
Jan 05
2021
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
333
-0.34%
|
$14,652
$44.95 P/Share
|